|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US4978672A
(en)
|
1986-03-07 |
1990-12-18 |
Ciba-Geigy Corporation |
Alpha-heterocyclc substituted tolunitriles
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4881175A
(en)
|
1986-09-02 |
1989-11-14 |
Genex Corporation |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5013653A
(en)
|
1987-03-20 |
1991-05-07 |
Creative Biomolecules, Inc. |
Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
|
|
EP0318554B2
(en)
|
1987-05-21 |
2005-01-12 |
Micromet AG |
Targeted multifunctional proteins
|
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
DE3884470T2
(de)
|
1987-06-17 |
1994-03-10 |
Sandoz Ag |
Cyclosporine und deren Benutzung als Arzneimittel.
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
|
JP2989002B2
(ja)
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
|
FR2650598B1
(fr)
|
1989-08-03 |
1994-06-03 |
Rhone Poulenc Sante |
Derives de l'albumine a fonction therapeutique
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
|
AU643109B2
(en)
|
1990-12-14 |
1993-11-04 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
FR2686901A1
(fr)
|
1992-01-31 |
1993-08-06 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
DK0563475T3
(da)
|
1992-03-25 |
2000-09-18 |
Immunogen Inc |
Konjugater af cellebindende midler og derivater af CC-1065
|
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
ATE427968T1
(de)
|
1992-08-21 |
2009-04-15 |
Univ Bruxelles |
Immunoglobuline ohne leichtkette
|
|
WO1994010202A1
(en)
|
1992-10-28 |
1994-05-11 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
|
SE9400088D0
(sv)
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
|
HUT76369A
(en)
|
1994-07-29 |
1997-08-28 |
Smithkline Beecham Corp |
Novel soluble protein compounds
|
|
WO2000073452A2
(en)
|
1999-06-02 |
2000-12-07 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
WO2000053753A2
(en)
|
1999-03-08 |
2000-09-14 |
Genentech, Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization
|
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
TW533205B
(en)
|
1996-06-25 |
2003-05-21 |
Novartis Ag |
Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
|
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
CA2263129C
(en)
|
1996-08-16 |
2007-01-09 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
SI1325932T1
(cg-RX-API-DMAC7.html)
|
1997-04-07 |
2005-08-31 |
Genentech Inc |
|
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
EP1695985B1
(en)
|
1997-04-07 |
2011-03-09 |
Genentech, Inc. |
Methods for forming humanised antibodies by random mutagenesis
|
|
EP0983303B1
(en)
|
1997-05-21 |
2006-03-08 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
|
DE19742706B4
(de)
|
1997-09-26 |
2013-07-25 |
Pieris Proteolab Ag |
Lipocalinmuteine
|
|
AU1102399A
(en)
|
1997-10-21 |
1999-05-10 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
|
US6689607B2
(en)
|
1997-10-21 |
2004-02-10 |
Human Genome Sciences, Inc. |
Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
|
US6503184B1
(en)
|
1997-10-21 |
2003-01-07 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
|
EP1053321A1
(en)
|
1998-02-09 |
2000-11-22 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
CA2325342A1
(en)
|
1998-04-08 |
1999-10-14 |
G.D. Searle & Co. |
Dual avb3 and metastasis-associated receptor ligands
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
CA2335653A1
(en)
|
1998-07-22 |
2000-02-03 |
Incyte Pharmaceuticals, Inc. |
Molecules associated with cell proliferation
|
|
AU3449899A
(en)
|
1998-08-13 |
2000-03-06 |
G.D. Searle & Co. |
Multivalent avb3 and Metastasis-Associated Receptor Ligands
|
|
JP2002531092A
(ja)
|
1998-12-01 |
2002-09-24 |
ジェネンテック・インコーポレーテッド |
腫瘍性細胞成長阻害のための組成物及び方法
|
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
|
CA2361849A1
(en)
|
1999-03-08 |
2000-09-14 |
Genentech, Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization
|
|
EP1220905A2
(en)
|
1999-03-08 |
2002-07-10 |
Genentech Inc. |
Composition and methods for the treatment of immune related diseases
|
|
PT1176195E
(pt)
|
1999-04-09 |
2013-07-18 |
Kyowa Hakko Kirin Co Ltd |
Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
|
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
|
ES2295040T3
(es)
|
1999-07-12 |
2008-04-16 |
Genentech, Inc. |
Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
|
|
DE19932688B4
(de)
|
1999-07-13 |
2009-10-08 |
Scil Proteins Gmbh |
Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
|
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
EP1803730A1
(en)
|
2000-04-12 |
2007-07-04 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7943129B2
(en)
|
2000-05-26 |
2011-05-17 |
National Research Council Of Canada |
Single-domain brain-targeting antibody fragments derived from llama antibodies
|
|
JP2004523205A
(ja)
|
2000-07-25 |
2004-08-05 |
イムノメディクス， インコーポレイテッド |
多価標的結合タンパク質
|
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
|
EP2351838A1
(en)
|
2000-10-20 |
2011-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Crosslinking agonistic antibodies
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US20050053973A1
(en)
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US20040175756A1
(en)
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
|
US20050048512A1
(en)
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
|
US20030133936A1
(en)
|
2001-07-12 |
2003-07-17 |
Byrne Michael Chapman |
CD25markers and uses thereof
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
CN1582150B
(zh)
|
2001-10-30 |
2011-09-07 |
诺瓦提斯公司 |
作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
|
|
WO2003064383A2
(en)
|
2002-02-01 |
2003-08-07 |
Ariad Gene Therapeutics, Inc. |
Phosphorus-containing compounds & uses thereof
|
|
TWI350285B
(en)
|
2002-03-13 |
2011-10-11 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
|
ES2345885T3
(es)
|
2002-11-15 |
2010-10-05 |
Novartis Vaccines And Diagnostics, Inc. |
Metodos para prevenir y tratar metastasis de cancer y perdida de hueso asociada con la metastasis de cancer.
|
|
CN100473664C
(zh)
|
2002-12-20 |
2009-04-01 |
拜奥根Idec马萨诸塞公司 |
多价淋巴毒素β受体激动剂及其治疗用途
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
WO2004060319A2
(en)
|
2002-12-30 |
2004-07-22 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
|
EP1611112B1
(en)
|
2003-02-11 |
2012-08-22 |
Vernalis (Cambridge) Limited |
Isoxazole compounds as inhibitors of heat shock proteins
|
|
WO2004072266A2
(en)
|
2003-02-13 |
2004-08-26 |
Kalobios Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
|
EP1462114A1
(en)
|
2003-03-28 |
2004-09-29 |
Universiteit Utrecht Holding B.V. |
Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
|
|
ZA200509143B
(en)
*
|
2003-05-23 |
2007-03-28 |
Wyeth Corp |
GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
|
|
JP4638876B2
(ja)
|
2003-05-23 |
2011-02-23 |
ワイス |
Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用
|
|
DE10324447A1
(de)
|
2003-05-28 |
2004-12-30 |
Scil Proteins Gmbh |
Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
US20050186208A1
(en)
|
2003-05-30 |
2005-08-25 |
Genentech, Inc. |
Treatment with anti-VEGF antibodies
|
|
WO2005007190A1
(en)
|
2003-07-11 |
2005-01-27 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
|
EP1682103A1
(en)
|
2003-10-27 |
2006-07-26 |
Novartis AG |
Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
|
|
JP2007518399A
(ja)
|
2003-12-02 |
2007-07-12 |
ジェンザイム コーポレイション |
肺癌を診断および治療する組成物並びに方法
|
|
BRPI0506726B8
(pt)
|
2004-01-07 |
2021-05-25 |
Chiron Corp |
anticorpo monoclonal específico para m-csf e usos deste
|
|
EP2990053A1
(en)
|
2004-01-20 |
2016-03-02 |
KaloBios Pharmaceuticals, Inc. |
Antibody specificity transfer using minimal essential binding determinants
|
|
US7626030B2
(en)
|
2004-01-23 |
2009-12-01 |
Amgen Inc. |
Compounds and methods of use
|
|
JP2007530588A
(ja)
|
2004-03-23 |
2007-11-01 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
レセプターカップリング剤およびその治療用途
|
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
WO2005113556A1
(en)
|
2004-05-13 |
2005-12-01 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
|
EP1765402A2
(en)
|
2004-06-04 |
2007-03-28 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
|
US20060008844A1
(en)
|
2004-06-17 |
2006-01-12 |
Avidia Research Institute |
c-Met kinase binding proteins
|
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
|
US20060009360A1
(en)
|
2004-06-25 |
2006-01-12 |
Robert Pifer |
New adjuvant composition
|
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
|
US20060099171A1
(en)
|
2004-11-05 |
2006-05-11 |
Masahide Tone |
Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
|
|
CA2587158C
(en)
|
2004-11-16 |
2016-01-12 |
Kalobios, Inc. |
Immunoglobulin variable region cassette exchange
|
|
WO2006074399A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
|
PL1850873T3
(pl)
|
2005-02-08 |
2019-06-28 |
Genzyme Corporation |
Przeciwciała przeciwko tgfbeta
|
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
|
US8034902B2
(en)
|
2005-05-04 |
2011-10-11 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against CD55 and CD59 and uses thereof
|
|
PT1877090E
(pt)
|
2005-05-06 |
2014-04-15 |
Providence Health System |
Proteína de fusão trimérica de imunoglobulina-ox40 e métodos de utilização
|
|
EP1896582A4
(en)
|
2005-05-09 |
2009-04-08 |
Ono Pharmaceutical Co |
HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
JP4984160B2
(ja)
|
2005-06-07 |
2012-07-25 |
国立大学法人 東京大学 |
抗体の作製方法
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
US8211648B2
(en)
|
2005-07-22 |
2012-07-03 |
Kalobios Pharmaceuticals, Inc. |
Secretion of antibodies without signal peptides from bacteria
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
|
TW200804345A
(en)
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
AR056142A1
(es)
|
2005-10-21 |
2007-09-19 |
Amgen Inc |
Metodos para generar el anticuerpo igg monovalente
|
|
EA016217B1
(ru)
|
2005-12-02 |
2012-03-30 |
Маунт Синай Скул Оф Медсин |
Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
|
|
UA116187C2
(uk)
|
2005-12-13 |
2018-02-26 |
Інсайт Холдінгс Корпорейшн |
ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
|
|
EP1963368B3
(en)
|
2005-12-13 |
2020-06-10 |
Eli Lilly And Company |
Anti-il-17 antibodies
|
|
DK2347775T3
(da)
|
2005-12-13 |
2020-07-13 |
Harvard College |
Skabeloner til celletransplantation
|
|
EP1981969A4
(en)
|
2006-01-19 |
2009-06-03 |
Genzyme Corp |
ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
CA2646508A1
(en)
|
2006-03-17 |
2007-09-27 |
Biogen Idec Ma Inc. |
Stabilized polypeptide compositions
|
|
ES2654847T3
(es)
|
2006-04-19 |
2018-02-15 |
Novartis Ag |
Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R
|
|
UA93548C2
(uk)
|
2006-05-05 |
2011-02-25 |
Айерем Елелсі |
Сполуки та композиції як модулятори хеджхогівського сигнального шляху
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
PE20110217A1
(es)
|
2006-08-02 |
2011-04-01 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
WO2008073160A2
(en)
|
2006-08-17 |
2008-06-19 |
The Trustees Of Columbia University In The City Of New York |
Methods for converting or inducing protective immunity
|
|
HRP20140081T1
(hr)
|
2006-08-18 |
2014-03-28 |
Novartis Ag |
Prlr-specifiäśna antitijela i njihova uporaba
|
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
AU2007323725B2
(en)
|
2006-11-22 |
2014-02-20 |
Incyte Holdings Corporation |
Imidazotriazines and imidazopyrimidines as kinase inhibitors
|
|
JP2010511731A
(ja)
|
2006-12-05 |
2010-04-15 |
メムジェン エルエルシー |
キメラｉｓｆ３５を利用した化学療法剤に対する癌感受性増強方法
|
|
WO2008073687A2
(en)
|
2006-12-08 |
2008-06-19 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
WO2008140621A2
(en)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Transgenic oncolytic viruses and uses thereof
|
|
JP2008278814A
(ja)
*
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
|
|
WO2008156712A1
(en)
|
2007-06-18 |
2008-12-24 |
N. V. Organon |
Antibodies to human programmed death receptor pd-1
|
|
WO2009002401A2
(en)
|
2007-06-21 |
2008-12-31 |
President And Fellows Of Harvard College |
Scaffolds for cell collection or elimination
|
|
NZ616254A
(en)
|
2007-06-27 |
2015-04-24 |
Us Sec Dep Of Health And Human Services |
Complexes of il-15 and il-15ralpha and uses thereof
|
|
AU2008275589B2
(en)
|
2007-07-12 |
2013-11-21 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
CA2694488A1
(en)
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
|
KR20100052545A
(ko)
|
2007-08-28 |
2010-05-19 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
|
|
US20090155255A1
(en)
|
2007-09-27 |
2009-06-18 |
Biogen Idec Ma Inc. |
Cd23 binding molecules and methods of use thereof
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
BRPI0907718A2
(pt)
|
2008-02-11 |
2017-06-13 |
Curetech Ltd |
método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
|
|
US10328133B2
(en)
|
2008-02-13 |
2019-06-25 |
President And Fellows Of Harvard College |
Continuous cell programming devices
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン， エルエルシー |
キナーゼ阻害剤および使用方法
|
|
PE20091628A1
(es)
|
2008-03-19 |
2009-11-19 |
Novartis Ag |
Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
|
|
WO2009131239A1
(ja)
|
2008-04-25 |
2009-10-29 |
Kyowa Hakko Kirin Co Ltd |
安定な多価抗体
|
|
MX393622B
(es)
|
2008-05-21 |
2025-03-24 |
Incyte Corp |
Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
|
|
JP5351254B2
(ja)
|
2008-05-23 |
2013-11-27 |
ノバルティス アーゲー |
キノキサリン−およびキノリン−カルボキシアミド誘導体
|
|
UY31929A
(es)
|
2008-06-25 |
2010-01-05 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
|
CA2729810A1
(en)
|
2008-07-02 |
2010-01-07 |
Emergent Product Development Seattle, Llc |
Tgf-.beta. antagonist multi-target binding proteins
|
|
WO2010006086A2
(en)
|
2008-07-08 |
2010-01-14 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
|
PL2315780T3
(pl)
|
2008-07-17 |
2016-01-29 |
Novartis Ag |
Kompozycje i sposoby zastosowania przeciwciał terapeutycznych
|
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
BRPI0917791B1
(pt)
|
2008-08-22 |
2022-03-22 |
Novartis Ag |
Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
|
|
EP2328919A2
(en)
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
EP2350129B1
(en)
|
2008-08-25 |
2015-06-10 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
|
BRPI0918268B1
(pt)
|
2008-09-02 |
2021-08-03 |
Novartis Ag |
Derivados de picolinamida, seu uso, e composição farmacêutica
|
|
WO2010028798A1
(en)
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Multivalent antibodies
|
|
UA104147C2
(uk)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
|
US8586023B2
(en)
|
2008-09-12 |
2013-11-19 |
Mie University |
Cell capable of expressing exogenous GITR ligand
|
|
EP2346508B1
(en)
|
2008-09-26 |
2016-08-24 |
Intellikine, LLC |
Heterocyclic kinase inhibitors
|
|
CN102227221A
(zh)
|
2008-11-28 |
2011-10-26 |
诺瓦提斯公司 |
包含hsp90抑制剂和mtor抑制剂的药物组合
|
|
TW202442680A
(zh)
|
2008-12-09 |
2024-11-01 |
美商建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
|
US20120029472A1
(en)
*
|
2008-12-19 |
2012-02-02 |
University Of Miami |
Tnfr25 agonists to enhance immune responses to vaccines
|
|
EP2987856B1
(en)
|
2009-02-05 |
2018-07-25 |
Icahn School of Medicine at Mount Sinai |
Chimeric newcastle disease viruses and uses thereof
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US8703132B2
(en)
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
|
KR101360725B1
(ko)
|
2009-06-26 |
2014-02-07 |
노파르티스 아게 |
Ｃｙｐ17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
|
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
|
IN2012DN01920A
(cg-RX-API-DMAC7.html)
*
|
2009-09-03 |
2015-07-24 |
Schering Corp |
|
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
AU2010328347B2
(en)
|
2009-12-07 |
2015-12-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for enhancing anti-tumor antibody therapy
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
WO2011090762A1
(en)
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Heterodimer binding proteins and uses thereof
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
CA3253628A1
(en)
|
2010-03-05 |
2025-11-29 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
JP6158511B2
(ja)
|
2010-06-11 |
2017-07-05 |
協和発酵キリン株式会社 |
抗ｔｉｍ−３抗体
|
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
|
US20120014947A1
(en)
*
|
2010-07-16 |
2012-01-19 |
The University Of Chicago |
Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
|
|
PH12013500333A1
(en)
|
2010-08-20 |
2013-04-22 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
ES2630328T3
(es)
|
2010-08-23 |
2017-08-21 |
Board Of Regents, The University Of Texas System |
Anticuerpos anti-OX40 y procedimientos de uso de los mismos
|
|
MX340556B
(es)
|
2010-08-24 |
2016-07-14 |
Roche Glycart Ag |
Anticuerpos biespecificos activables.
|
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
|
ES2651170T3
(es)
|
2010-09-21 |
2018-01-24 |
Altor Bioscience Corporation |
Moléculas de fusión solubles multímeras de IL-15 y métodos para elaborar y usar las mismas
|
|
EP2624873B1
(en)
|
2010-10-06 |
2019-12-04 |
President and Fellows of Harvard College |
Injectable, pore-forming hydrogels for materials-based cell therapies
|
|
EP2655624B1
(en)
|
2010-12-23 |
2017-11-29 |
Biogen MA Inc. |
Linker peptides and polypeptides comprising same
|
|
ES2685327T3
(es)
|
2011-04-28 |
2018-10-08 |
President And Fellows Of Harvard College |
Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
|
|
JP6400470B2
(ja)
|
2011-05-16 |
2018-10-03 |
ジェネロン（シャンハイ）コーポレイション リミテッド |
多重特異性Ｆａｂ融合タンパク質および使用法
|
|
BR112013030958B1
(pt)
|
2011-06-03 |
2022-02-08 |
Xoma Technology Ltd |
Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
|
|
EP2714073B1
(en)
|
2011-06-03 |
2021-03-10 |
President and Fellows of Harvard College |
In situ antigen-generating cancer vaccine
|
|
WO2012178137A1
(en)
|
2011-06-24 |
2012-12-27 |
Gillies Stephen D |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
WO2013049254A1
(en)
|
2011-09-26 |
2013-04-04 |
Jn Biosciences Llc |
Hybrid constant regions
|
|
US9382319B2
(en)
|
2011-09-26 |
2016-07-05 |
Jn Biosciences Llc |
Hybrid constant regions
|
|
EP2771022B1
(en)
|
2011-10-11 |
2020-07-01 |
Viela Bio, Inc. |
Cd40l-specific tn3-derived scaffolds and methods of use thereof
|
|
MX349096B
(es)
|
2011-11-28 |
2017-07-11 |
Merck Patent Gmbh |
Anticuerpos anti-pd-l1 y sus usos.
|
|
AU2013207687B2
(en)
|
2012-01-13 |
2017-11-30 |
Dana-Farber Cancer Institute, Inc. |
Controlled delivery of TLR agonists in structural polymeric devices
|
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
US20150086584A1
(en)
|
2012-03-22 |
2015-03-26 |
University Of Miami |
Multi-specific binding agents
|
|
CA2868787A1
(en)
|
2012-03-29 |
2013-10-03 |
Advanced Cancer Therapeutics, Llc |
Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic
|
|
LT2838515T
(lt)
|
2012-04-16 |
2020-03-10 |
President And Fellows Of Harvard College |
Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui
|
|
PT2838548T
(pt)
|
2012-04-17 |
2023-10-13 |
Univ Washington Through Its Center For Commercialization |
Células deficientes em hla de classe ii, células deficientes em hla de classe i capazes de expressar proteínas de hla de classe ii, e utilizações das mesmas
|
|
EA201492007A1
(ru)
|
2012-05-15 |
2015-03-31 |
Новартис Аг |
Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
|
|
AU2013261129B2
(en)
|
2012-05-15 |
2016-05-12 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
|
PE20210667A1
(es)
|
2012-05-15 |
2021-04-05 |
Novartis Ag |
Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
|
|
CN104379574B
(zh)
|
2012-05-15 |
2017-03-01 |
诺华股份有限公司 |
用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
|
|
JO3300B1
(ar)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات لتعديل نشاط egfr
|
|
KR101566539B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
EP2880057A4
(en)
|
2012-08-02 |
2016-03-23 |
Jn Biosciences Llc |
MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL
|
|
TWI472974B
(zh)
|
2012-09-06 |
2015-02-11 |
Au Optronics Corp |
多類物體觸控點偵測方法
|
|
CA2888896A1
(en)
|
2012-10-24 |
2014-05-01 |
Admune Therapeutics Llc |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
|
AU2013343425A1
(en)
|
2012-11-08 |
2015-06-11 |
Novartis Ag |
Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
|
|
JP2016501221A
(ja)
|
2012-11-28 |
2016-01-18 |
ノバルティス アーゲー |
併用療法
|
|
SMT201900242T1
(it)
|
2012-12-03 |
2019-05-10 |
Bristol Myers Squibb Co |
Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
|
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
|
SG11201505330QA
(en)
|
2013-02-08 |
2015-08-28 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
WO2014141104A1
(en)
|
2013-03-14 |
2014-09-18 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
CA2905272A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Newcastle disease viruses and uses thereof
|
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
|
CN105188373B
(zh)
|
2013-05-18 |
2017-09-22 |
艾杜罗生物科技公司 |
抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法
|
|
CU24377B1
(es)
|
2013-05-18 |
2018-12-05 |
Aduro Biotech Inc |
Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
ES2684360T3
(es)
|
2013-11-01 |
2018-10-02 |
Novartis Ag |
Aminoheteroaril benzamidas como inhibidores de quinasa
|
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|